Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon

详细信息    查看全文

• 作者：Corinne Tchoula Mamiafo (8)
  Vicky Jocelyne Ama Moor (6) (7)
  Jobert Richie N Nansseu (9)
  Constant Anatole Pieme (7)
  Claude Tayou (10)
  Jeanne Ngogang Yonkeu (6) (7)
  
• 关键词：Hyperlactatemia ; Antiretroviral therapy ; HIV ; First line regimen
• 刊名：AIDS Research and Therapy
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：11
• 期：1
• 全文大小：263 KB
• 作者单位：Corinne Tchoula Mamiafo (8)
  Vicky Jocelyne Ama Moor (6) (7)
  Jobert Richie N Nansseu (9)
  Constant Anatole Pieme (7)
  Claude Tayou (10)
  Jeanne Ngogang Yonkeu (6) (7)
  
  8. Department of Biochemistry, Faculty of Sciences, University of Yaounde I, Yaounde, Cameroon
  6. Laboratory of Biochemistry, Yaounde University Teaching Hospital, Yaounde, Cameroon
  7. Department of Biochemistry and Physiological Sciences, University of Yaounde I, Yaounde, Cameroon
  9. Intensive Care Unit, Mother and Child Centre, Chantal Biya Foundation, Yaounde, Cameroon
  10. Laboratory of Hematology, Yaounde University Teaching Hospital, Yaounde, Cameroon
  
• ISSN：1742-6405

文摘

Background and aim Prolonged exposure to highly active antiretroviral therapy (HAART) is associated with adverse effects such as hyperlactatemia. We determined the prevalence and risk factors for developing hyperlactatemia among human immunodeficiency virus (HIV)-infected cameroonians on antiretroviral therapy (ART). Methods We conducted a cross-sectional study from January to April 2012 involving 91 HIV-infected patients receiving ART for at least 12 months and 30 HIV-infected patients who have never received ART (ART-na?ve patients). Plasma lactate levels were determined after at least 12 hours of overnight fasting and hyperlactatemia defined as lactate concentrations?≥-?mmol/L. The prevalence of hyperlactatemia was determined and the risk factors were analyzed by a multivariate logistic regression model. Results The mean lactataemia was significantly higher in the group of HIV patients currently taking ART than in the ART-na?ve one (2.3?±-.3 and 1.7?±-.7?mmol/L respectively, p--.002). Patients on first line ART regimens had significantly higher lactatemia than those on second line regimens (2.5?±-.5 and 1.9?±-.7?mmol/L respectively, p--.014). The prevalence of hyperlactatemia in HIV patients receiving ART and in ART-na?ve HIV patients was respectively 18.7 and 6.7% (p--.095). ART-exposure (adjusted odds ratio (aOR) 5.44, 95% confidence interval (CI) 1.06 -27.84; p--.042) and being on a first line regimen (aOR 16.22, 95% CI 1.57 -167.91; p--.019) were independent strong predictors of hyperlactatemia. Conclusion Hyperlactatemia was not rare in our study population. Being on a first line regimen constitutes an important risk factor for developing hyperlactatemia. Measurement of plasma lactate may be useful in optimizing the management of HIV-positive persons on ART.